<DOC>
	<DOCNO>NCT01211938</DOCNO>
	<brief_summary>Patients randomise surgery , provide surgery macroscopically adequate , flap tissue protect vascular axis wound heal allows reirradiation begin less 8 week surgery.Reirradiation begin two arm less 8 week surgery irradiated area . The reirradiated volume : tumour bed + safety margin &lt; 2 cm immediate protection bone marrow . This volume jointly define radiotherapist surgeon . During reirradiation , 60 Gy deliver two arm last 11 week reference arm 5 week investigational arm.Acute toxicity ( NCI-CTCAE ) evaluate end reirradiation 6 month randomization ( first follow-up consultation )</brief_summary>
	<brief_title>Trial Comparing Two Protocols Irradiation Irradiated Area Carcinoma Upper Aerodigestive Tract</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Recurrent second upper aerodigestive tract carcinoma area previously irradiate dose &gt; = 50 Gy Squamous cell carcinoma No grade III IV sequel link first radiation therapy ( except radiation sequel salivary gland ) Relapse second carcinoma ( clinically invasive and/or lymph node recurrence &gt; = 3 cm and/or association local lymph node recurrence Oral cavity , pharynx , larynx ( rT4 ) , cervical region ( &gt; 3cm ) No distant metastasis confirm chest CT scan , abdominal ultrasound ( CT scan ) case abnormal liver function , bone scintigraphy case local symptom Surgery previously irradiate region allow macroscopically adequate resection Surgery vascular protection myocutaneous free flap Interval &gt; = 6 month end first radiation treatment surgery previously irradiate area Wound heal allow reirradiation within interval 8 week surgery previouly irradiated area . No participation clinical trial 30 day precede inclusion Age 18 et 70 year . Performance Status 0 1 accord WHO criterion . Hematological function : neutrophil * 2 x 106/l , platelet : * 100 x 106/l , hemoglobin : * 10 g/dl ( 6.2 mmol/l ) Liver function : total bilirubin ( normal ) ; ASAT ( SGOT ) ALAT ( SGPT ) * 2.5 * upper limit normal ( ULN ) centre ; alkaline phosphatase * 5 * ULN . Patients whose ASAT ALAT level &gt; 1.5 * ULN associate alkaline phosphatase * 2.5 * ULN eligible trial Renal function : serum creatinine * 120 *mol/l ( 1.4 mg/dl ) ; creatinine level &gt; 120 *mol/l , creatinine clearance * 60 ml/min . Written consent participant Superficial recurrence associate lymph node relapse , isolated lymph node recurrence measure less 3 cm Distant metastases Grade 3 4 sequel first radiation therapy ( excepted salivary gland sequel ) Macroscopically inadequate surgery Delay wound heal oblige reirradiation postpone beyond 8 week . &gt; Grade 3 Toxicity induce chemotherapy administer previous treatment Hypersensitivity Erbitux Concomitant severe comorbidities ( non exhaustive list ) Unstable cardiac comorbidity spite treatment . Neurological psychiatric history dementia , convulsion . Severe uncontrolled infection Obstructive bronchopneumopathy require hospitalisation year precede inclusion . Factors ( psychological , familial , social geographic ) likely hinder patient compliance study protocol followup consider exclusion criterion . These factor discuss patient enrollment trial Women pregnant , breastfeed birthgiving age without effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>phase II/III</keyword>
	<keyword>upper aerodigestive tract carcinoma</keyword>
	<keyword>irradiation</keyword>
	<keyword>Recurrent second upper aerodigestive tract carcinoma</keyword>
</DOC>